Skip to main content Accessibility help
×
Home
Hostname: page-component-684bc48f8b-zqvvz Total loading time: 0.438 Render date: 2021-04-11T12:55:55.665Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": false, "newCiteModal": false, "newCitedByModal": true }

Recurrence rates in stable bipolar disorder patients after drug discontinuation v. drug maintenance: a systematic review and meta-analysis

Published online by Cambridge University Press:  13 October 2020

Taro Kishi
Affiliation:
Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi 470-1192, Japan
Yuki Matsuda
Affiliation:
Department of Psychiatry, Jikei University School of Medicine, Minato-ku, Tokyo, 105-8461, Japan
Kenji Sakuma
Affiliation:
Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi 470-1192, Japan
Makoto Okuya
Affiliation:
Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi 470-1192, Japan
Kazuo Mishima
Affiliation:
Department of Neuropsychiatry, Akita University Graduate School of Medicine, Akita, Japan
Nakao Iwata
Affiliation:
Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi 470-1192, Japan
Corresponding
E-mail address:

Abstract

Background

This random-effects model meta-analysis of double-blind, randomized placebo-controlled trials compared recurrence rates in bipolar disorder (BD) patients between antipsychotic/mood stabilizer discontinuation and maintenance groups.

Methods

We conducted systematic literature search of Embase, PubMed, and CENTRAL databases without language restriction from inception until 22 May 2020. Independent investigators assessed studies and extracted data. We calculated risk ratios (RRs) and numbers needed to benefit or harm (NNTB/NNTH). Primary outcome was the recurrence rate of any mood episode at 6 months. Secondary outcomes were recurrence rates of depressive episodes and manic/hypomanic/mixed episodes and all-cause discontinuation at 6 months. We also investigated these outcomes at 1, 3, 9, 12, 18, and 24 months.

Results

We identified 22 studies (n = 5462) receiving aripiprazole, asenapine, divalproex, long-acting injectable (LAI)-aripiprazole, LAI-risperidone, lamotrigine, lithium, olanzapine, paliperidone, or quetiapine. Mean study duration was 64.50 ± 69.35 weeks. The maintenance group demonstrated lower recurrence rates of any mood episode, depressive episodes, and manic/hypomanic/mixed episodes as well as reduced all-cause discontinuation at every observational point. The RRs (95% confidence interval, NNTB/NNTH) of recurrence rate at 6 months were 0.61 (0.54–0.70, 5) for any mood episode, 0.72 (0.60–0.87, 13) for depressive episodes, and 0.45 (0.36–0.57, 6) for manic/hypomanic/mixed episodes. The RR for all-cause discontinuation at 6 months was 0.71 (0.61–0.82, 6).

Conclusions

Maintaining drug treatment during clinically stable BD prevented recurrence for up to 24 months. Discontinuation of medications for ⩾1 month significantly increased recurrence risk. However, 47.3% of patients who discontinued drugs for 6 months did not experience recurrence.

Type
Original Articles
Copyright
Copyright © The Author(s), 2020. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below.

References

Amsterdam, J. D., & Shults, J. (2010). Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: A randomized, double-blind, placebo-substitution study. The American Journal of Psychiatry, 167(7), 792800. doi: 10.1176/appi.ajp.2009.09020284.CrossRefGoogle ScholarPubMed
Benjamini, Y., & Hochberg, Y. (1995). Controlling the false discovery rate: A practical and powerful approach to multiple testing. Journal of the Royal Statistical Society. Series B (Methodological), 57(1), 289300.CrossRefGoogle Scholar
Berwaerts, J., Melkote, R., Nuamah, I., & Lim, P. (2012). A randomized, placebo- and active-controlled study of paliperidone extended-release as maintenance treatment in patients with bipolar I disorder after an acute manic or mixed episode. Journal of Affective Disorders, 138(3), 247258. doi: 10.1016/j.jad.2012.01.047.CrossRefGoogle ScholarPubMed
Blonde, L., Khunti, K., Harris, S. B., Meizinger, C., & Skolnik, N. S. (2018). Interpretation and impact of real-world clinical data for the practicing clinician. Advances in Therapy, 35(11), 17631774. doi: 10.1007/s12325-018-0805-y.CrossRefGoogle ScholarPubMed
Bowden, C. L., Calabrese, J. R., McElroy, S. L., Gyulai, L., Wassef, A., Petty, F., … Wozniak, P. J. (2000). A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Archives of General Psychiatry, 57(5), 481489. doi: 10.1001/archpsyc.57.5.481.CrossRefGoogle ScholarPubMed
Bowden, C. L., Calabrese, J. R., Sachs, G., Yatham, L. N., Asghar, S. A., Hompland, M., … Lamictal 606 Study, G. (2003). A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Archives of General Psychiatry, 60(4), 392400. doi:10.1001/archpsyc.60.4.392.CrossRefGoogle ScholarPubMed
Calabrese, J. R., Bowden, C. L., Sachs, G., Yatham, L. N., Behnke, K., Mehtonen, O. P., … Lamictal 605 Study, G. (2003). A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. The Journal of Clinical Psychiatry, 64(9), 10131024. doi:10.4088/jcp.v64n0906.CrossRefGoogle ScholarPubMed
Calabrese, J. R., Sanchez, R., Jin, N., Amatniek, J., Cox, K., Johnson, B., … Carson, W. H. (2017). Efficacy and safety of aripiprazole once-monthly in the maintenance treatment of bipolar I disorder: A double-blind, placebo-controlled, 52-week randomized withdrawal study. The Journal of Clinical Psychiatry, 78(3), 324331. doi: 10.4088/JCP.16m11201.CrossRefGoogle ScholarPubMed
Calabrese, J. R., Suppes, T., Bowden, C. L., Sachs, G. S., Swann, A. C., McElroy, S. L., … Monaghan, E. T. (2000). A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. The Journal of Clinical Psychiatry, 61(11), 841850. doi: 10.4088/jcp.v61n1106.CrossRefGoogle ScholarPubMed
Cundall, R. L., Brooks, P. W., & Murray, L. G. (1972). A controlled evaluation of lithium prophylaxis in affective disorders. Psychological Medicine, 2(3), 308311. doi: 10.1017/s0033291700042616.CrossRefGoogle ScholarPubMed
DerSimonian, R., & Laird, N. (1986). Meta-analysis in clinical trials. Controlled Clinical Trials, 7(3), 177188.CrossRefGoogle ScholarPubMed
Dunner, D. L., Stallone, F., & Fieve, R. R. (1976). Lithium carbonate and affective disorders. V: A double-blind study of prophylaxis of depression in bipolar illness. Archives of General Psychiatry, 33(1), 117120. doi: 10.1001/archpsyc.1976.01770010073014.CrossRefGoogle ScholarPubMed
Fieve, R. R., Kumbaraci, T., & Dunner, D. L. (1976). Lithium prophylaxis of depression in bipolar I, bipolar II, and unipolar patients. The American Journal of Psychiatry, 133(8), 925929. doi: 10.1176/ajp.133.8.925.Google ScholarPubMed
Grande, I., Berk, M., Birmaher, B., & Vieta, E. (2016). Bipolar disorder. Lancet (London, England), 387(10027), 15611572. doi: 10.1016/S0140-6736(15)00241-X.CrossRefGoogle ScholarPubMed
Higgins, J. P., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003). Measuring inconsistency in meta-analyses. BMJ: British Medical Journal, 327(7414), 557560. doi: 10.1136/bmj.327.7414.557.CrossRefGoogle ScholarPubMed
Kane, J. M., Quitkin, F. M., Rifkin, A., Ramos-Lorenzi, J. R., Nayak, D. D., & Howard, A. (1982). Lithium carbonate and imipramine in the prophylaxis of unipolar and bipolar II illness: A prospective, placebo-controlled comparison. Archives of General Psychiatry, 39(9), 10651069. doi: 10.1001/archpsyc.1982.04290090053011.CrossRefGoogle ScholarPubMed
Keck, P. E. Jr., Calabrese, J. R., McIntyre, R. S., McQuade, R. D., Carson, W. H., Eudicone, J. M., … Aripiprazole Study, G. (2007). Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: A 100-week, double-blind study versus placebo. The Journal of clinical psychiatry, 68(10), 14801491. doi:10.4088/jcp.v68n1003.CrossRefGoogle ScholarPubMed
Kishi, T., Oya, K., & Iwata, N. (2016). Long-acting injectable antipsychotics for prevention of relapse in bipolar disorder: A systematic review and meta-analyses of randomized controlled trials. The International Journal of Neuropsychopharmacology, 19(9), pyw038. doi: 10.1093/ijnp/pyw038.CrossRefGoogle ScholarPubMed
Koyama, T., Higuchi, T., Yamawaki, S., Kanba, S., Terao, T., & Shinohara, A. (2011). Study SCA104779, an evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar I disorder patients. Japanese Journal of Clinical Psychiatry, 40(3), 369383.Google Scholar
Lahteenvuo, M., Tanskanen, A., Taipale, H., Hoti, F., Vattulainen, P., Vieta, E., & Tiihonen, J. (2018). Real-world effectiveness of pharmacologic treatments for the prevention of rehospitalization in a finnish nationwide cohort of patients with bipolar disorder. JAMA Psychiatry, 75(4), 347355. doi: 10.1001/jamapsychiatry.2017.4711.CrossRefGoogle Scholar
Melia, P. I. (1970). Prophylactic lithium: A double-blind trial in recurrent affective disorders. The British Journal of Psychiatry: The Journal of Mental Science, 116(535), 621624. doi: 10.1192/bjp.116.535.621.CrossRefGoogle ScholarPubMed
Miura, T., Noma, H., Furukawa, T. A., Mitsuyasu, H., Tanaka, S., Stockton, S., … Kanba, S. (2014). Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: A systematic review and network meta-analysis. The Lancet. Psychiatry, 1(5), 351359. doi: 10.1016/S2215-0366(14)70314-1.CrossRefGoogle ScholarPubMed
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & Group, P. (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ: British Medical Journal, 339, b2535. doi: 10.1136/bmj.b2535.CrossRefGoogle ScholarPubMed
Prien, R. F., Caffey, E. M. Jr., & Klett, C. J. (1973). Prophylactic efficacy of lithium carbonate in manic-depressive illness. Report of the Veterans Administration and National Institute of Mental Health collaborative study group. Archives of General Psychiatry, 28(3), 337341. doi:10.1001/archpsyc.1973.01750330035006.CrossRefGoogle ScholarPubMed
Prien, R. F., Klett, C. J., & Caffey, E. M. Jr. (1973). Lithium carbonate and imipramine in prevention of affective episodes. A comparison in recurrent affective illness. Archives of General Psychiatry, 29(3), 420425. doi:10.1001/archpsyc.1973.04200030104017.CrossRefGoogle ScholarPubMed
Quiroz, J. A., Yatham, L. N., Palumbo, J. M., Karcher, K., Kushner, S., & Kusumakar, V. (2010). Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biological Psychiatry, 68(2), 156162. doi: 10.1016/j.biopsych.2010.01.015.CrossRefGoogle ScholarPubMed
Szegedi, A., Durgam, S., Mackle, M., Yu, S. Y., Wu, X., Mathews, M., & Landbloom, R. P. (2018). Randomized, double-blind, placebo-controlled trial of asenapine maintenance therapy in adults with an acute manic or mixed episode associated with bipolar I disorder. The American Journal of Psychiatry, 175(1), 7179. doi: 10.1176/appi.ajp.2017.16040419.CrossRefGoogle ScholarPubMed
Tohen, M., Calabrese, J. R., Sachs, G. S., Banov, M. D., Detke, H. C., Risser, R., … Bowden, C. L. (2006). Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. The American Journal of Psychiatry, 163(2), 247256. doi: 10.1176/appi.ajp.163.2.247.CrossRefGoogle ScholarPubMed
Vieta, E., Montgomery, S., Sulaiman, A. H., Cordoba, R., Huberlant, B., Martinez, L., & Schreiner, A. (2012). A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder. European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology, 22(11), 825835. doi: 10.1016/j.euroneuro.2012.03.004.CrossRefGoogle ScholarPubMed
Weisler, R. H., Nolen, W. A., Neijber, A., Hellqvist, A., Paulsson, B., & Trial 144 Study, I. (2011). Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (trial 144: A randomized controlled study). The Journal of Clinical Psychiatry, 72(11), 14521464. doi:10.4088/JCP.11m06878.CrossRefGoogle Scholar
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., … Berk, M. (2018). Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disorders, 20(2), 97170. doi: 10.1111/bdi.12609.CrossRefGoogle ScholarPubMed
Young, A. H., McElroy, S. L., Olausson, B., Paulsson, B., Embolden, I., & Embolden, I. I. I. (2014). A randomised, placebo-controlled 52-week trial of continued quetiapine treatment in recently depressed patients with bipolar I and bipolar II disorder. The World Journal of Biological Psychiatry, 15(2), 96112. doi: 10.3109/15622975.2012.665177.CrossRefGoogle ScholarPubMed

Kishi et al. supplementary material

Kishi et al. supplementary material

PDF 1 MB

Altmetric attention score

Full text views

Full text views reflects PDF downloads, PDFs sent to Google Drive, Dropbox and Kindle and HTML full text views.

Total number of HTML views: 68
Total number of PDF views: 142 *
View data table for this chart

* Views captured on Cambridge Core between 13th October 2020 - 11th April 2021. This data will be updated every 24 hours.

Linked content

Please note a has been issued for this article.

Send article to Kindle

To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Recurrence rates in stable bipolar disorder patients after drug discontinuation v. drug maintenance: a systematic review and meta-analysis
Available formats
×

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

Recurrence rates in stable bipolar disorder patients after drug discontinuation v. drug maintenance: a systematic review and meta-analysis
Available formats
×

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

Recurrence rates in stable bipolar disorder patients after drug discontinuation v. drug maintenance: a systematic review and meta-analysis
Available formats
×
×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *